Lumen Integrates with Connect IQ to Provide Garmin Users Metabolic Data to Improve Their Performance and Health
11.11.2020 13:00:00 EET | Business Wire | Press release
Lumen, the world’s first hand-held metabolic tracking device, together with Garmin® International, Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), have launched a Connect IQ Lumen App and Garmin Health API integration, allowing users to better understand the impact of fitness and nutrition decisions on their body in real time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201111005049/en/
Lumen and Garmin integration (Photo: Lumen)
Through the CO2 concentration in a single breath, Lumen measures your metabolic health and provides daily personalised nutrition plans and insights into what your body is burning - fats or carbs. Lumen supports fat burn and improves your metabolic flexibility, which is your body's ability to efficiently switch between using carbs and fats as a fuel source.
Garmin activity trackers and smartwatches help you track and share your activities. Thanks to Lumen data and the Garmin Health API integration, Garmin users can now seamlessly integrate their health and activity data such as heart rate, sleep, steps and calories burned, into the Lumen app and instantly optimise their fitness journey.
“We are thrilled to work with Garmin on this crucial integration. We know how important it is for our users to get valuable insights into their fitness and this will allow them to make more informed decisions about their nutrition and improve their metabolic health,” said Lumen CEO, Daniel Tal.
By combining Garmin and Lumen data, users will be able to monitor their carb fuel consumption through notifications that guide them on when to breathe into Lumen and unlock their day or take a post workout breath. Users can now see how their workout affects their metabolism through recovery macros and a comprehensive Garmin workout summary.
“Lumen is an innovative organisation pushing the boundaries on metabolic health and performance optimisation. Garmin’s Connect IQ platform will enable users to act in real-time to make the right fitness and nutrition decisions at every moment,” said Sean McNamara, Garmin Health Senior Manager Sales and Marketing.
For continual metabolic tracking, Garmin users with compatible devices will also have access to crucial Lumen data such as morning insights, daily and weekly Lumen levels and the Lumen Flex Score which indicates the degree of metabolic flexibility. The goal is to make sure that nutrition and metabolic health remain top of mind.
About Garmin Health
Engineered on the inside for life on the outside, Garmin products have revolutionised the wellness industry. Garmin Health provides enterprise solutions that leverage Garmin wearables and the high-quality sensor data they produce for applications in the corporate wellness, population health, and patient monitoring markets. For more information, visit garmin.com/health, contact the Media Relations department at 913-397-8200, or follow us at facebook.com/garmin, twitter.com/garminnews, instagram.com/garminwellness or youtube.com/garmin.
About Garmin Connect IQ
Connect IQ is the app system for Garmin wearables, bike computers, and outdoor handhelds. Connect IQ allows developers to create on-device solutions for Garmin users. Developers use the Connect IQ SDK to develop apps, and then upload their creations to the Connect IQ store. From there, millions of Garmin users can browse thousands of apps including Starbucks, Spotify, and Amazon Music for download to their Connect IQ compatible device.
About Lumen
Lumen is a device and app that measures your metabolism in a single breath through a complex algorithm and provides daily personalised nutrition based on your metabolic data. At Lumen, we believe that a healthy metabolism is the key to better health, and that everyone can attain it with a little help from Lumen.
Founded in 2014 by scientists and experienced entrepreneurs, Lumen is the biggest metabolic measurement platform in the world, with over 1,000,000 measurements per month. Lumen’s vision is to improve the world's metabolic health and quality of life by empowering individuals to make smarter decisions about their nutrition and lifestyle. Our technology provides individuals with new metrics on metabolism and a system to keep them accountable so they can achieve their health and wellness goals and prevent long-term chronic illness by improving their metabolic health.
Follow us at twitter.com/LumenMetabolism, facebook.com/Lumen.me/, instagram.com/lumen.me/, youtube.com/c/Lumendotme
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005049/en/
Contact information
Press
press@lumen.me
+972548161939
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom